Crohn-beteg gyermekek infliximabkezelésének kezdeti tapasztalatai hazánkban

Translated title of the contribution: Analysis of infl iximab treated pediatric patients with Crohn disease in Hungary

G. Verès, Dolóresz Szabó, A. Várkonyi, Beáta Tari, Marianne Polgár, J. Kovács, Ágnes Horváth, Erika Tomsits, István Tokodi, Hedvig Bodánszky, Antal Dezsofi, Erzsébet Szakos, Noémi Vass, Viktória Ruszinkó, Márta Kovács, Katalin Eszter Müller, A. Arató

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8%) achieved clinical response, and 13 patients (59.1%) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70% at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.

Original languageHungarian
Pages (from-to)179-183
Number of pages5
JournalOrvosi Hetilap
Volume151
Issue number5
DOIs
Publication statusPublished - Jan 1 2010

Fingerprint

Hungary
Crohn Disease
Pediatrics
Therapeutics
Fistula
Infliximab
Tumor Necrosis Factor-alpha
Observation
Medicine
Antibodies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Crohn-beteg gyermekek infliximabkezelésének kezdeti tapasztalatai hazánkban. / Verès, G.; Szabó, Dolóresz; Várkonyi, A.; Tari, Beáta; Polgár, Marianne; Kovács, J.; Horváth, Ágnes; Tomsits, Erika; Tokodi, István; Bodánszky, Hedvig; Dezsofi, Antal; Szakos, Erzsébet; Vass, Noémi; Ruszinkó, Viktória; Kovács, Márta; Müller, Katalin Eszter; Arató, A.

In: Orvosi Hetilap, Vol. 151, No. 5, 01.01.2010, p. 179-183.

Research output: Contribution to journalArticle

Verès, G, Szabó, D, Várkonyi, A, Tari, B, Polgár, M, Kovács, J, Horváth, Á, Tomsits, E, Tokodi, I, Bodánszky, H, Dezsofi, A, Szakos, E, Vass, N, Ruszinkó, V, Kovács, M, Müller, KE & Arató, A 2010, 'Crohn-beteg gyermekek infliximabkezelésének kezdeti tapasztalatai hazánkban', Orvosi Hetilap, vol. 151, no. 5, pp. 179-183. https://doi.org/10.1556/OH.2010.28792
Verès, G. ; Szabó, Dolóresz ; Várkonyi, A. ; Tari, Beáta ; Polgár, Marianne ; Kovács, J. ; Horváth, Ágnes ; Tomsits, Erika ; Tokodi, István ; Bodánszky, Hedvig ; Dezsofi, Antal ; Szakos, Erzsébet ; Vass, Noémi ; Ruszinkó, Viktória ; Kovács, Márta ; Müller, Katalin Eszter ; Arató, A. / Crohn-beteg gyermekek infliximabkezelésének kezdeti tapasztalatai hazánkban. In: Orvosi Hetilap. 2010 ; Vol. 151, No. 5. pp. 179-183.
@article{3aaf74f3d36741319c3b15487c04239c,
title = "Crohn-beteg gyermekek infliximabkezel{\'e}s{\'e}nek kezdeti tapasztalatai haz{\'a}nkban",
abstract = "Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8{\%}) achieved clinical response, and 13 patients (59.1{\%}) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70{\%} at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.",
keywords = "Activity index, Crohn disease, Infliximab, Pediatric",
author = "G. Ver{\`e}s and Dol{\'o}resz Szab{\'o} and A. V{\'a}rkonyi and Be{\'a}ta Tari and Marianne Polg{\'a}r and J. Kov{\'a}cs and {\'A}gnes Horv{\'a}th and Erika Tomsits and Istv{\'a}n Tokodi and Hedvig Bod{\'a}nszky and Antal Dezsofi and Erzs{\'e}bet Szakos and No{\'e}mi Vass and Vikt{\'o}ria Ruszink{\'o} and M{\'a}rta Kov{\'a}cs and M{\"u}ller, {Katalin Eszter} and A. Arat{\'o}",
year = "2010",
month = "1",
day = "1",
doi = "10.1556/OH.2010.28792",
language = "Hungarian",
volume = "151",
pages = "179--183",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "5",

}

TY - JOUR

T1 - Crohn-beteg gyermekek infliximabkezelésének kezdeti tapasztalatai hazánkban

AU - Verès, G.

AU - Szabó, Dolóresz

AU - Várkonyi, A.

AU - Tari, Beáta

AU - Polgár, Marianne

AU - Kovács, J.

AU - Horváth, Ágnes

AU - Tomsits, Erika

AU - Tokodi, István

AU - Bodánszky, Hedvig

AU - Dezsofi, Antal

AU - Szakos, Erzsébet

AU - Vass, Noémi

AU - Ruszinkó, Viktória

AU - Kovács, Márta

AU - Müller, Katalin Eszter

AU - Arató, A.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8%) achieved clinical response, and 13 patients (59.1%) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70% at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.

AB - Infliximab, the chimeric antibody to tumor necrosis factor-alpha, is indicated for medically refractory pediatric Crohn disease. Aim of our study was to examine the efficacy and side effects of infliximab therapy in Hungarian pediatric patients with Crohn disease since the authorisation of medicine for children to 31.12.2008. 23 children with refractory Crohn disease received infliximab during this period. Induction therapy with 5 mg/kg infliximab at weeks 0, 2, and 6 was introduced. 18 patients (81.8%) achieved clinical response, and 13 patients (59.1%) were in remission at the 6th week of the observation period. The evaluation was based on data of 22 children. Fistula closure rate was 70% at the at the 6th week. Two patients had acute infusion reaction, one had severe anaphilactic reaction after infliximab infusion. Chronic side effects were also observed in three cases. In our study infliximab induction therapy was effective in most pediatric patients with therapy refractory Crohn disease.

KW - Activity index

KW - Crohn disease

KW - Infliximab

KW - Pediatric

UR - http://www.scopus.com/inward/record.url?scp=76249118851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76249118851&partnerID=8YFLogxK

U2 - 10.1556/OH.2010.28792

DO - 10.1556/OH.2010.28792

M3 - Article

C2 - 20083466

AN - SCOPUS:76249118851

VL - 151

SP - 179

EP - 183

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 5

ER -